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Abstract 
Background: Elevated lipoprotein (a) [Lp(a)] is an independent risk factor for coronary artery disease (CAD). 
However, there is little evidence about the therapeutic efficacy of different lipid-lowering agents in reducing Lp(a). 
Objective: The primary objective of our study was to test the effect of different therapeutic treatment strategies on 
elevated Lp(a) levels, specifically to compare rosuvastatin versus atorvastatin alone or in combination with niacin or 
fibrates. The secondary objective was to analyze the occurrence of potential adverse effects. Methods: It was a 
prospective, single-center, interventional study. Patients with CAD, or high CAD risk, with increased Lp(a), >50 mg/dL, 
were included in the study. Lp(a), total cholesterol (C), triglycerides (TGs), high-density lipoprotein cholesterol and low-
density lipoprotein cholesterol (LDL-C), apolipoprotein (Apo) A1, Apo B, and enzymes of myocyte and hepatic injury 
were comparatively analyzed between 4 lipid-lowering treatment strategies: rosuvastatin (R group) 40 mg, atorvastatin 
(A group) 80 mg, atorvastatin 40 mg add-on micronized fenofibrate (A+F group), and atorvastatin 40 mg add-on 1 g 
extended-release niacin (A+ERN group). Comparison was made for their lipid lowering therapeutic efficacy, primarily on 
Lp(a), and their safety profile. Results: A total of 87 patients, 61 ± 12 years old, were analyzed. The main risk factors 
were obesity (64.7%) and hypertension (64.6%). Men were more often smokers (odds ratio [OR] = 5.1) and had CAD 
(OR = 2.8), but lower total C (206.9 ± 32.9 vs 238.6 ± 47.9 mg/dL, P = 0.002) and LDL-C (136.5 ± 18.2 vs 160.9 ± 30.9 
mg/dL, P = 0.000). Mean Lp(a) was 94.6 ± 39.6 mg/dL, without significant gender difference. There were 25 patients in 
the R group, 22 in the A group, and 20 each in the A+F and A+ERN groups. Significant reduction in all lipid fractions in 
all treatment groups was reported after 6 months. The average reduction of Lp(a) was 15.9 ± 21.0 mg/dL, with 18.2 ± 
24.8 (P = 0.001) in the R group and similar values in the A+F and A+ERN groups (17.3 ± 10.4, P = 0.001, and 19.5 ± 10.9, 
P = 0.001, respectively), and the lowest in the A group (11.24 ± 22.91, P = 0.032). No adverse effects were observed in 
any of the treatment groups. Conclusions: When compared with atorvastatin, it seems that rosuvastatin can achieve a 
statistically more significant decrease of Lp(a). The efficacy of atorvastatin on the Lp(a) optimization can be increased by 
adding either fibrate or ERN. Given in recommended doses, all agents were well tolerated.[AQ1] 
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Introduction 
Lipoprotein (a) [Lp(a)] comprises a low-density lipid 
fraction and protein component apoprotein (a) [apo(a)]. 
Lp(a) levels are genetically determined, and remain 
relatively stable over a lifetime. Elevated Lp(a) is an 
independent risk factor for coronary artery disease 
(CAD).1,2 Mean values of Lp(a) gathered from a 
Framingham Study cohort were 14 mg/dL for men, and 15 
mg/dL for women, with a standard deviation of 17 mg/dL 
for both genders. Levels above 50 mg/dL are considered 
elevated.1,2 
There is a recommendation in the 2011 ESC/EAS 
Guidelines for the Treatment of Dyslipidemias, for the 
measurement of Lp(a) in individuals with a strong family 
history of ischemic heart disease or with premature CAD 
but not in the general population (IIa, loe C[AQ2]).2-4 The 
European Atherosclerosis Society also recommends 
screening for elevated Lp(a) in those at intermediate or 
high cardiovascular disease (CVD)/coronary heart disease 
risk, with a desirable level of less than 50 mg/dL.5 
Elevated Lp(a) was identified as a risk factor in the 2013 
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American College of Cardiology/American Heart 
Association Guidelines on the Treatment of Blood 
Cholesterol to Reduce Atherosclerotic Cardiovascular Risk 
in Adults, but without screening or treatment 
recommendations.6 
There is little evidence about the therapeutic efficacy of 
different lipid-lowering agents in reducing Lp(a). Nicotinic 
acid (niacin) is one of the first drugs used to treat high 
Lp(a) that was proven to be effective.2,7 It was also the 
only drug recommended by the European Atherosclerosis 
Society Consensus panel in 2010.5 In recent years, 2 meta-
analyses by Takagi and coworkers have been published on 
the effectiveness of statins in general and rosuvastatin, 
specifically, in the treatment of elevated Lp(a).8-10 
Our intent was to evaluate the efficacy of different 
lipid-lowering agents in lowering Lp(a) levels in the 
Macedonian population. 
The Aim of the Study 
The primary aim was to compare the therapeutic efficacy 
of different statins—rosuvastatin versus atorvastatin 
alone—in combination with extended-release niacin 
(ERN) or micronized fenofibrate in lowering increased 
Lp(a). The secondary aim was to compare their efficacy on 
other lipoprotein (LP) fractions. We also aimed to compare 
the safety profile of the prescribed medications, especially 
when used as a combination therapy. 
Material and Methods 
This was a prospective, open-label, interventional, single-
center study that aimed to compare the efficacy of 
different lipid-lowering strategies, including: rosuvastatin 
and atorvastatin, the latter alone and in combination with 
ERN or micronized fenofibrate. The study was approved 
by the institutional review board, and all patients gave 
written informed consent. 
Participants were >18 years old with an indication for 
statin therapy as a result of their primary condition (CAD 
or high SCORE [Systematic COronary Risk Evaluation] 
risk) and were also found to have significantly increased 
level of Lp(a) (>50 mg/dL). 
Analyzed Variables 
The variables analyzed were age, gender, risk factors for 
CAD, comorbidities, SCORE risk (for patients without 
confirmed CAD: http://www.heartscore.org), laboratory 
parameters (hemogram, blood urea, creatinine, glucose, 
myoglobin, creatine phosphokinase [CPK], aspartate and 
alanine transaminase [AST and ALT]), LP fractions 
(Lp(a), cholesterol [C], triglycerides [TGs], HDL-C, and 
LDL-C, apolipoprotein [Apo] A1, and Apo B), and 
medications used (cardiovascular, for associated 
conditions and lipid lowering). 
Patients were randomly assigned to 1 of 4 treatment 
regimens: rosuvastatin group (R), initial dose of 20 mg 
was uptitrated to 40 mg on the first control visit (8-12 
weeks) if no adverse effects were reported; atorvastatin 
group (A); atorvastatin add-on micronized fenofibrate 
group (A+F); and atorvastatin add-on ERN group 
(A+ERN). For atorvastatin, the initial dose was 40 mg, and 
on the first control visit (8-12 weeks), if no adverse effects 
occurred, patients were either uptitrated to 80 mg or 145 
mg micronized fenofibrate or 1 g ERN was added 
(decision made on patients’ preference). The patients 
remained on the same treatment regimen for 6 months. 
The major exclusion criteria were CPK ≥3× upper limit 
of normal (ULN), ALT ≥1.5× ULN, AST ≥1.5× ULN, 
calculated creatinine clearance <30 mL/min, hemoglobin 
A1C (A1C) ≥9%, persistent uncontrolled hypertension (on 
triple antihypertensive therapy without achieved arterial 
hypertension treatment targets), and pregnancy and 
lactation. 
Data were collected from medical history, clinical 
examination, and blood sampling. Blood sampling was 
repeated on an 8- to 12-week basis during the treatment 
period. Methods used for LP fraction determination are 
described in the appendix. Comparison was made between 
the 4 treatment regimens as regards their therapeutic 
efficacy and safety profile. 
Statistical Analysis 
Descriptive statistics were in terms of absolute values, 
percentages, and means ± SD. Comparative statistics were 
in terms of the χ2 test, odds ratios (ORs; with CI), t-test, 
and ANOVA (with the post hoc Tukey test). Significance 
was determined at a level of <0.05. 
Results 
We screened 250 patients with dyslipidemia, 87 of whom 
met the criterion of Lp(a) >50 mg/dL and were enrolled in 
the study. The mean age of the patients was 61.0 ± 12.1 
years, and men predominated (56.3%); 56.9% of the 
patients had CAD, others were with high CVD risk. 
Overweight and/or obesity (64.4%) and hypertension 
(64.4%) were the predominant risk factors. Only 18.3% 
had diabetes. Men had an OR = 5.1 for smoking and 2.8 
for CAD as compared with women, whereas women had 
higher SCORE risk. Lp(a) ranged from 52 to 183 mg/dL 
(mean = 94.63 ± 39.55 mg/dL), with men having higher 
levels but without statistical significance (Table 1). 
Comparative gender analysis of LP fractions revealed that 
women had significantly higher total C and LDL-C. 
Patients were divided into 4 groups of treatment. There 
were no significant differences in the levels of the LP 
fractions between the groups at the beginning of the 
treatment (Table 2). 
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Table 1. Baseline Characteristics of the Patients.a 
Variable Total, n (%) of Total Men, n (%) Women, n (%) Significance (P) 
Gender 87 49 (56.3%) 38 (43.7%)  
Age (years) 61.0 ± 12.1 61.5 ± 11.0 62.7 ± 12.7 ns 
BMI (kg/m2) 27.2 ± 3.9 26.9 ± 3.7 28.3 ± 4.4 ns 
 Normal weight (19.9-24.9) 31 (35.6%) 20 (40.8%) 11 (28.9%)  
 Overweight (25-29.9) 36 (41.4%) 16 (32.6%) 20 (52.6%) ns 
 Obese >30 20 (23.0%) 13 (26.6%) 7 (18.5%)  
Smoking 23 (26.4%) 19 (38.8%) 4 (10.5%) 0.013 (OR/M = 5.1; CI = 1.3-19.9) 
Diabetes mellitus 16 (18.4%) 11 (22.4%) 5 (13.1%) ns (OR/M = 1.6; CI = 0.6-6.4) 
HTA  56 (64.4%) 34 (69.4%) 22 (57.9%) ns (OR/M = 1.4; CI = 0.7-2.7) 
Comorbidities 
 CAD patients 49 (56.3%) 34 (69.4%) 15 (39.5%) 0.041 (OR/M = 2.8; CI = 1.0-7.7) 
 SCORE risk  38 (43.7%) 15 (30.6%) 23 (60.5%)  
  Mean SCORE risk 8.2 ± 4.1 6.7 ± 3.3 10.5 ± 4.2 0.010 
  High SCORE risk, n 28 (32.2%) 12 (24.5%) 16 (42.1%) 0.050 
  Very high SCORE risk, n 10 (11.5%) 3 (6.1%) 7 (18.4%)  
Medications 
 ACE inhibitor 60 (69.0%) 35 (71.4%) 25 (65.8%) ns 
 ARBs 16 (18.4%) 12 (24.5%) 4 (10.2%) ns 
 Diuretics 33 (37.9%) 19 (39.6%) 14 (36.8%) ns 
 MRA 10 (11.5%) 10 (20.4%) 0 (0%) 0.008 (OR/M = 4.05; CI = 0.1-6.9) 
 BB 56 (64.4%) 32 (65.3%) 24 (63.1%) ns 
 CCB 25 (28.7%) 15 (30.6%) 10 (26.3%) ns 
 Antiplatelets 74 (85.0%) 45 (91.8%) 29 (74.3%) ns 
 OAK 8 (9.2%) 4 (8.2%) 4 (10.5%) ns 
DM treatment 
 Insulin 4 (4.6%) 4 (8.2%) 0  
 OH 7 (8.0%) 3 (6.1%) 4 (10.5%) ns 
 OH+Insulin 5 (5.7%) 4 (8.2%) 1 (2.6%)  
Lipoprotein fraction (mg/dL) 
 C 220.4 ± 42.9 206.9 ± 32.9 238.6 ± 47.9 0.002 
 TG 219.7 ± 116.0 202.8 ± 84.1 240.9 ± 146.1 ns 
 LDL-C 146.9 ± 27.1 136.5 ± 18.2 160.9 ± 30.9 0.000 
 HDL-C 44.8 ± 10.4 46.0 ± 9.7 43.3 ± 10.8 ns 
 Apo A1 144 ± 27 144 ± 29 144 ± 26 ns 
 Apo B 93 ± 28 88 ± 19 99 ± 36 ns 
 Lp(a) 94.63 ± 39.55 99.91 ± 40.88 87.61 ± 37.3 ns 
Abbreviations: ACE, angiotensin-converting enzyme; Apo, apolipoprotein; ARB, angiotensin receptor blocker; ASA, aspirin; BB, β-blockers; BMI, body 
mass index; C, cholesterol; CAD, coronary artery disease; CCB, calcium channel blocker; DM, diabetes mellitus; F, females; HDL-C, high-density 
lipoprotein cholesterol; HTA, arterial hypertension; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); M, males; MRA, 
mineralocorticoid receptor antagonist; OAK, oral anticoagulant medication; OH, oral hypoglycemic medications; OR, odds ratio; SCORE, Systematic 
COronary Risk Evaluation; TG, triglycerides. 
a
 Only values with statistical significance (P < 0.05) are expressed as numbers. The results are shown as means with SDs, percentages, and as odds 
ratios with CIs. 
Table 2. Distribution of the Patients in Accordance With the Antilipemic Treatment and Lipoprotein Levels at Study Entrance.a 
Treatment 
Groups (%) C (mg/dL) HDL-C (mg/dL) LDL-C (mg/dL) TG (mg/dL) Apo A1 (mg/dL) Apo B (mg/dL) Lp(a) (mg/dL) 
R (29%) 209.98 ± 39.06 44.47 ± 8.89 144.62 ± 20.88 208.15 ± 96.54 144 ± 21 93 ± 31 95.67 ± 35.95 
A (25%) 238.98 ± 42.92 44.47 ± 10.83 153.52 ± 29.39 215.23 ± 62.89 147 ± 26 99 ± 28 97.35 ± 50.32 
A+F (23%) 213.07 ± 45.24 44.08 ± 14.69 143.08 ± 32.48 186.89 ± 115.94 133 ± 42 93 ± 17 87.07 ± 13.89 
A+N (23%) 212.68 ± 42.54 47.56 ± 9.67 142.30 ± 34.03 295.84 ± 156.77 148 ± 32 75 ± 21 92.59 ± 41.32 
Total (100%) 220.42 ± 42.92 44.86 ± 10.44 146.94 ± 27.07 219.66 ± 116.03 144 ± 27 93 ± 28 94.63 ± 39.55 
ANOVA 
significance 
ns ns ns ns ns ns ns 
Abbreviations: A, atorvastatin; A+F, atorvastatin add-on micronized fenofibrate group; A+ERN, atorvastatin add-on extended-release niacin group; 
Apo, apolipoprotein; C, cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); R, 
rosuvastatin; TG, triglycerides. 
a
 The results are shown as mean values with SDs. Treatment groups are shown as percentages of total number. 
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Therapeutic Efficacy 
The primary outcome of interest was Lp(a). Statistically 
significant reduction of Lp(a) was observed in all 
treatment groups (Table 3). The reduction was similar in 
R, A+E, and A+ERN groups (P = 0.001). The lowest mean 
reduction rate was observed in group A (P = 0.032). 
However, at the end of the treatment period, only 16.9% of 
all patients reached the target value of <50 mg/dL Lp(a) 
without significant intertreatment differences. 
Regarding efficacy on other LP fractions, all treatments 
were equally potent in the reduction of total C, LDL-C, 
and TG. The effect on HDL-C varied between different 
treatments. The most significant increase was observed in 
the rosuvastatin group, followed by atorvastatin and 
A+ERN groups, but none was observed in the A+F group. 
Both statins were equally effective in increasing Apo A1 
and decreasing Apo B, whereas the combination therapy 
proved ineffective. 
Safety 
During the treatment period, no major adverse effects were 
reported in any of the treatment groups. No flushing or 
muscle pain was reported by the patients, and no 
significant increase in skeletal or hepatic enzymes was 
observed (Table 4). 
Discussion 
Clinical Significance of Lp(a) 
Lp(a) is a well-known risk factor for atherosclerosis, with 
a linear correlation between Lp(a) values and CVD risk. 
The risk associated with elevated Lp(a) is reported to be 
higher in women (Shai et al,[AQ3] from the Nurses’ 
Health Study). The Copenhagen City Heart Study reports a 
stepwise increase in the risk of myocardial infarction with 
increasing levels of Lp(a), which is similar in both 
genders. Similar results were found in a meta-analysis of 
12 prospective studies performed by Craig and 
coauthors,[AQ4] The Reykjavik Study, The Bruneck 
Study, The ARIC study, and The PRIME Study.2,3 
However, up to date, there is no clear evidence of the 
therapeutic efficacy of lipid-lowering agents on Lp(a). 
Also, there is a lack of evidence that Lp(a) lowering will 
result in cardiovascular risk reduction.1,2,4 Our study aimed 
to test the effect of different therapeutic treatment 
strategies on elevated Lp(a) levels. We selected a group of 
patients with very high Lp(a) levels (94.6 ± 39.6 mg/dL; 
Table 1). 
Screening and Treatment Targets for Lp(a) 
Currently, Lp(a) measurement is recommended for people 
with high CAD risk, premature CV events, or a strong 
familial history of premature CAD.4,5 These were the 
characteristics of our population (Table 1). The 
recommendation from EAS is that Lp(a) levels should be 
≤50 mg/dL.5 But Lp(a) levels are genetically determined 
and remain constant throughout the lifetime; also, data 
show that current therapies are unable to reduce elevated 
Lp(a) to an acceptable level.11 This was the case in our 
study as well. Significant reduction was observed with all 
treatments, with a mean reduction of the Lp(a) level after 
treatment to 77.25 ± 36.08 mg/dL (P = 0.001), although 
only 16.9% of patients achieved the target level of <50 
mg/dL during the treatment period. 
Treatment Strategies: Role of Lipid-Lowering Agents 
in Elevated Lp(a) Treatment 
Several lipid-lowering agents are reported to effectively 
decrease the Lp(a) levels, among them niacin, fibrates and 
statins.2,12-14 
Niacin. Niacin was among the first lipid-lowering agents 
proven to be effective in Lp(a) treatment, with a possible 
decrease of Lp(a) by ∼20% to 30%. Until a few years ago, 
it was considered to be the best drug option, with a 
disadvantage of requiring very high doses, as reported by 
Carlson[AQ5] (4 g/d), which were associated with many 
adverse effects. The ER formulation was used in doses of 
1 to 3 g/d, with significantly reduced adverse effects.7 Pan 
et al15 reported that ERN is effective in Lp(a) reduction 
even in the treatment of diabetic dyslipidemias, 
independently of A1C levels. In the COMPELL study, 
where 4 treatment regiments were tested, the statin/ERN 
combination lead to an ∼40% reduction of Lp(a), with 
negligible adverse effects.16 Effective Lp(a) lowering may 
be dependent on the type of lipid abnormalities associated 
with high Lp(a), the dose of niacin, type of formulation, 
time of treatment, and so on. 2,7,12,13,15 The effect of niacin 
on cardiovascular outcomes is uncertain. The HPS2-
THRIVE trial found an increased risk of myopathy, 
diabetes, and increased ALT, without CVD risk reduction, 
when 2 g of ERN/LRPT[AQ6] were added to statin 
therapy, despite its beneficial effect on LP fractions (Lp(a) 
was not a subject of analysis in this study).17 
In our study, the A+ERN group was associated with the 
highest mean reduction in Lp(a) (19.54 ± 10.86 mg/dL), 
with the same statistical significance as rosuvastatin and 
A+F treatments (P = 0.001). Efficacy on total C, LDL-C, 
HDL-C, and TG was somewhat smaller than with statin 
monotherapy and inferior for Apo A1 and Apo B (Table 
3). Patients did not develop any adverse effects (but it may 
be because of the low 1-g/d dosage as well as the fact that 
it was not a combination of ERN/LRPT, a combination 
that could have been the cause of the adverse reactions 
reported in HPS2-THRIVE).17 
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Table 3. Mean Values of Lipoprotein (LP) Fractions at the Beginning and End of Treatment as a Function of Antilipemic Treatment.a 
LP Fraction 
Treatment 
Rosuvastatin (R) Atorvastatin (A) 
Atorvastatin Add-on 
Fibrate (A+F) 
Atorvastatin Add-on 
Niacin (A+ERN) Total 
Lp(a) Ib 95.67 ± 35.95 97.35 ± 50.32 87.07 ± 13.89 92.59 ± 41.32 94.63 ± 39.55 
Lp(a) IIc 77.47 ± 34.11 86.11 ± 42.25 69.73 ± 20.33 73.06 ± 32.62 77.25 ± 36.08 
Delta Lp(a)  18.20 ± 24.77 11.24 ± 22.91 17.34 ± 10.36 19.54 ± 10.86 17.32 ± 34.06 
Significance (P) 0.001 0.032 0.001 0.001 0.001 
C Ib 209.98 ± 39.05 238.98 ± 42.92 213.07 ± 45.24 212.68 ± 42.54 183.35 ± 42.92 
C IIc 157.38 ± 31.71 183.29 ± 38.67 165.51 ± 24.36 156.99 ± 40.22 154.68 ± 36.74 
Delta C 52.59 ± 33.25 55.68 ± 32.09 47.56 ± 32.48 34.80 ± 35.58 28.55 ± 38.52 
Significance (P) 0.000 0.000 0.002 0.020 0.000 
HDL-C Ib 44.47 ± 8.89 44.47 ± 10.83 44.08 ± 14.69 47.56 ± 9.67 44.86 ± 10.44 
HDL-C IIc 48.34 ± 10.05 49.88 ± 14.69 49.11 ± 10.44 62.64 ± 19.72 49.49 ± 12.76 
Delta HDL-C  3.87 ± 5.03 5.41 ± 10.05 4.64 ± 7.35 15.08 ± 16.63 4.63 ± 11.26 
Significance (P) 0.001 0.021 0.93(ns) 0.027 0.000 
LDL-C Ib 144.62 ± 20.88 153.52 ± 29.39 143.08 ± 32.48 142.30 ± 34.02 146.94 ± 27.07 
LDL-C IIc 94.35 ± 28.23 114.46 ± 35.19 105.57 ± 17.01 100.93 ± 33.25 98.99 ± 28.23 
Delta LDL-C  50.27 ± 20.88 39.05 ± 30.93 37.51 ± 30.55 41.38 ± 24.36 46.96 ± 30.23 
Significance (P) 0.000 0.000 0.007 0.001 0.000 
TG Ib 208.15 ± 96.54 215.23 ± 62.89 186.89 ± 15.94 285.84 ± 245.35 219.66 ± 116.03 
TG IIc 137.29 ± 65.54 133.75 ± 52.26 99.20 ± 15.05 178.03 ± 136.40 147.03 ± 116.92 
Delta TG  70.86 ± 69.09 79.71 ± 61.11 87.69 ± 20.37 117.80 ± 116.03 71.66 ± 98.91 
Significance (P) 0.000 0.000 0.000 0.016 0.003 
Apo A1 Ib 144 ± 21 147 ± 26 133 ± 42 148 ± 32 144 ± 27 
Apo A1 IIc 156 ± 24 156 ± 27 149 ± 23 152 ± 27 155 ± 24 
Delta Apo A1  12 ± 22 09 ± 15 15 ± 25 50 ± 11 12 ± 29 
Significance (P) 0.014 0.011 0.100 (ns) 0.224 (ns) 0.032 
Apo B Ib 93 ± 31 99 ± 28 93 ± 17 75 ± 21 93 ± 28 
Apo B IIc 78 ± 23 86 ± 26 82 ± 16 76 ± 22 82 ± 24 
Delta Apo B  15 ± 19 13 ± 18 11 ± 24 01 ± 09 10 ± 14 
Significance (P) 0.001 0.004 0.201 (ns) 0.835 (ns) 0.002 
Abbreviations: Apo, apolipoprotein; C, cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), 
lipoprotein (a); TG, triglycerides. 
a
 The results are shown as mean values with standard deviations. 
b
 I: values at the beginning. 
c
 II: values at the end of the treatment period. 
Table 4. Safety Profile (Effect on Liver and Skeletal Muscle, Expressed Through Markers of Hepatic Cell and Skeletal Muscle Cell 
Injury) as a Function of Antilipemic Treatment.a 
Treatment Beginning (I)/End (II) Myoglobin (µg/L) CPK (µkat/L) AST (µkat/L) ALT (µkat/L) 
Rosuvastatin I 2.17 ± 0.51 1.28 ± 0.76 0.55 ± 0.35 0.65 ± 0.49 
II 2.63 ± 1.31 1.34 ± 0.63 0.37 ± 0.18 0.42 ± 1 = 0.17 
Atorvastatin I 2.16 ± 0.85 1.41 ± 0.83 0.39 ± 0.16 0.62 ± 0.39 
II 2.11 ± 0.51 1.47 ± 0.76 0.30 ± 0.12 0.40 ± 0.13 
Atorvastatin + Fenofibrate I 2.68 ± 0.34 1.71 ± 0.29 0.32 ± 0.18 0.40 ± 0.21 
II 2.11 ± 0.85 1.73 ± 1.08 0.35 ± 0.13 0.38 ± 0.20 
Atorvastatin + ERN  I 2.11 ± 0.22 1.63 ± 0.97 0.64 ± 0.25 0.84 ± 0.55 
II 2.56 ± 0.86 1.65 ± 0.49 0.34 ± 0.08 0.39 ± 0.19 
ANOVA significance (P)  ns ns ns ns 
Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; ERN, extended-release niacin. 
a
 The results are shown as mean values with standard deviations. 
 
Fenofibrate. Fibrates also demonstrated some Lp(a)-
lowering effects, but no large-scale trials evaluating 
fenofibrates and Lp(a) have been published.2 Markel7 
reports that several studies have demonstrated 
antiatherosclerotic action for both niacin and fibrates. But, 
in the ACCORD trial lipid arm, intensive lipid-lowering 
treatment with combined statin-fibrate therapy did not leаd 
to reduction in CV events. So despite the fact that fibrates 
are effective in reduction of sdLDL[AQ7] particles, it 
does not necessarily translate to CVD risk reduction.18 
In our study, we found that A+F treatment led to a 
significant decrease of Lp(a) (17.34 ± 10.36; P = 0.001), 
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similar to the R and A+ERN treatments. It was also 
effective in TG and LDL-C lowering, but not in the 
lowering of other LP fractions (Table 3). 
Statins. The effects of statins on Lp(a) levels are variable, 
especially depending on the statin that is used. 
Plenge[AQ8] reported that simvastatin moderately 
increases Lp(a) in individuals with increased C. In the 
COMPELL study, atorvastatin led to modest but 
significant reductions in Lp(a).14 Gonbert et al19 also 
reported similar findings. In the REGRESS Study, 
pravastatin therapy had a small effect on Lp(a). In the 
JUPITER Trial, a small but statistically significant 
decrease of Lp(a) was observed with rosuvastatin.2,8-10 
Takagi and coworkers8,10 conducted the first meta-analysis 
of the effect of statins on Lp(a), reporting that statins do 
have a favorable effect on Lp(a), with rosuvastatin being 
the most potent among them. 
In our study, a more favorable effect across all LP 
fractions was observed with rosuvastatin in comparison to 
atorvastatin. The former led to a more pronounced effect 
on Lp(a). This can be a result of their pharmacokinetic 
differences (hydrosolubility vs liposolubility, less 
dependence of rosuvastatin on circulating transport 
proteins, hepatic enzyme activation, etc). 
Limitations of the Study 
One limitation is the small sample size (the results might 
have been different if we had had a larger study 
population). The low dose of ERN used (1 g) might 
influence study results, although some of the clinical trials 
reported a dosage in the range of 0.5 to 2 g. We would like 
to emphasize that the aim of our study was not to 
determine the clinical effects of Lp(a) lowering, given the 
fact that a study like that would mean a follow-up period 
of at least several years. 
Learning Points 
According to our results, statins alone, or in combination 
with fibrates or ERN, can decrease Lp(a), with 
rosuvastatin demonstrating higher statistical significance 
in comparison to atorvastatin when used as monotherapy. 
However, even more important is the finding that in 
patients with significantly increased levels of Lp(a), it is 
very difficult to achieve a target level of <50 mg/dL, no 
matter which lipid-lowering agent is used and what dosage 
regimen is followed. 
Conclusion 
When compared with atorvastatin, it seems that 
rosuvastatin can achieve a more significant decrease of 
Lp(a). While equally effective in optimizing total C, LDL-
C, TG, Apo A1, and Apo B, rosuvastatin was also found to 
be more effective in increasing HDL-C. Efficacy of 
atorvastatin on the Lp(a) can be increased by adding either 
fibrate or ERN, but adding these agents has no benefit on 
optimization of Apos. Effect on HDL-C differs between 
fibrate and ERN (when added to statin therapy), with the 
latter demonstrating a significant increase of HDL-C. Used 
in recommended doses, even as a combination therapy, 
these medications were shown to be well tolerated and free 
of major adverse effects. 
Appendix 
Methods to Determine LP Fractions: Determination 
of Lipid and LP Components 
Determination of Total C Concentration in Serum or Plasma. 
Total cholesterol was measured enzymatically in serum or 
plasma in a series of coupled reactions that hydrolyze 
cholesterol esters and oxidize the 3-OH group of 
cholesterol. One of the reaction byproducts, H2O2 was 
measured quantitatively in a peroxidase catalyzed reaction 
that produces a color. Absorbance was measured at 500 
nm. The color intensity is proportional to cholesterol 
concentration. 
Determination of TGs in Serum or Plasma. TGs in serum or 
plasma were also measured using enzymatic methods 
using a series of coupled reactions in which TGs were 
hydrolyzed to produce glycerol. Glycerol is then oxidized 
using glycerol oxidase, and H2O2, one of the reaction 
products, was measured as described above for total 
cholesterol. Absorbance is measured at 500 nm. 
Determination of HDL-C Concentration in Serum or Plasma. 
The HDL measurement was done directly in serum. The 
basic principle of the method is as follows: the Apo B–
containing LPs in the specimen were reacted with a 
blocking reagent that renders them nonreactive with the 
enzymatic cholesterol reagent under conditions of the assay. 
The Apo B–containing LPs were, thus, effectively excluded 
from the assay, and only HDL-C is detected under the assay 
conditions. This reaction results in a colored solution, whose 
absorbance is measured at 600 nm. 
Determination of LDL-C Concentration in Serum or Plasma. 
Concentration of LDL cholesterol was estimated using the 
direct colorimetric method based on a combination of 
sugar compounds with detergents. These mixtures enable 
selective determination of LDL, with end reaction that 
includes peroxidase and results in blue quinoneimine. 
Intensity and increase of absorbance is measured at 583 
nm and is proportional to LDL-C concentration. 
Determination of Apo A and Apo B in Serum or Plasma. 
Determination of Apo A1 as well as Apo B was based on 
the immunoturbidimetric principle during which Apo 
A1/Apo B is precipitate with specific antiserum and 
measured turbid metrically at 340 nm. 
Vavlukis et al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Determination of Lp(a) in Serum or Plasma. 
Immunoturbidimetric method enhanced by particle was 
used in determination of this Lp(a). LPs from serum 
agglutinate with latex particles coated with specific anti-
Lp(a) antibody. Formed precipitate is turbid metrically 
measured at 552 nm. 
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